Treatment with sumifilam significantly lowered the levels of multiple biomarkers of disease activity, neurodegeneration, and inflammation in people with mild-to-moderate Alzheimer’s after 28 days of treatment, according to final data from a Phase 2b trial. Sumifilam, Cassava Sciences’ lead investigational candidate for Alzheimer’s disease, also was found to be safe and well-tolerated, and to improve patients’ cognitive function, compared with a placebo. “Other than a few drugs to help ease the decline, there’s really nothing…
You must be logged in to read/download the full post.
The post Sumifilam Lowers Levels of Multiple Biomarkers of Disease Activity, Trial Shows appeared first on BioNewsFeeds.